trending Market Intelligence /marketintelligence/en/news-insights/trending/WycWRFvquSGvf0bwSLQ2Xw2 content esgSubNav
In This List

Aclaris plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aclaris plans common stock offering

Aclaris Therapeutics Inc. plans to sell up to $75 million of its common stock in an underwritten public offering.

The company will grant underwriters an option to buy up to an additional $11.3 million of common stock.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Co. LLC, Guggenheim Securities LLC, and JMP Securities LLC are acting as co-managers for the offering.